Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Publication | Closed Access

DOI

385

Citations

References

2017

Year

Paul E. Sax, Anton Pozniak, Marisa Montes, Ellen Koenig, Edwin DeJesus, Hans-Jürgen Stellbrink, Andrea Antinori, Kimberly Workowski, Jihad Slim, Jacques Reynes,

The Lancet

Hiv/aids CounsellingAntiviral Drug DevelopmentAntiviral TherapyAntiviral ResponseVirologyPharmacotherapyHiv-1 InfectionNon-inferiority TrialTenofovir AlafenamideHivAntiviral DrugMedicineViral ImmunityAids Pathogenesis